Another rationale for abemaciclib in prophylactic and therapeutic settings is the fact that aberrant CDK4/6 function triggers tumor immune evasion and orchestrates an immunologically cold TME [35,36] – regardless of tumor mutational burden. The gene discussed is CDK4; the disease is neoplasm.